Oklo Inc. (NYSE:OKLO) closed at $52.36 on July 2, ahead of the U.S. Independence Day holiday, as the company approaches a critical regulatory milestone. The stock posted a 4.7% gain over the four-session week, though it remained 7.1% below its Thursday high of $56.34, reflecting a volatile session that saw shares swing approximately 10.8% from their close.
According to the latest data, short interest in Oklo stands at 27.22 million shares, representing 19.29% of the float. This short position is valued at roughly $1.65 billion, equivalent to about 18% of the company's market capitalization. The elevated short interest suggests significant bearish sentiment, even as the company progresses toward operational milestones.
On Wednesday, the U.S. Department of Energy approved the Documented Safety Analysis for Oklo Isotopes' Groves Isotope Test Reactor in Texas, part of the DOE Reactor Pilot Program. The final steps now include a DOE readiness review and startup approval, after which Oklo will proceed with fuel receipt, fuel loading, startup testing, and first criticality. CEO Jacob DeWitte described Groves as "that demonstration" that now "moves into the final phase before startup."
The Groves reactor, as noted by Barron's, is not intended for electricity generation but rather focuses on radioisotope production. This distinction is important for investors, as Oklo's larger Aurora power project remains a separate initiative. The Groves milestone is primarily about establishing credibility and demonstrating the company's ability to execute on its technology.
Oklo's market cap stood at $9.11 billion as of the July 2 close, with volume reaching 9.68 million shares. The company's valuation is approximately 3.6 times the $2.54 billion in cash, cash equivalents, and marketable securities reported on March 31. Despite the lack of revenue, Oklo posted a net loss of $33.1 million in the first quarter and an operating loss of $51.2 million.
Analyst sentiment is divided, with 10 buy ratings versus seven holds over the past three months, according to Google Finance. The average 12-month price target stands at $90.08. Craig-Hallum's Eric Stine rates the stock a hold as of July 1, while Guggenheim's Joseph Osha also rates it a hold with a $54.06 target as of June 25. B. Riley Securities' Ryan Pfingst maintains a buy with a $92 target, and UBS's Jon Windham rates it a hold at $55.
The coming week will be pivotal as the market digests the DOE decision and whether the stock can break above last week's high near $56. Oklo continues to target first criticality for Groves in July 2026, pending the DOE's readiness review and final startup approval.
